Predictors of Health-Related QOL in Adults With CLL or Small Lymphocytic Lymphoma
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Bruton's tyrosine kinase inhibitor, B-Cell Lymphoma 2 Protein Inhibitor.
- Who it may be relevant to
- Registry conditions: Small Lymphocytic Lymphoma (SLL), Chronic Lymphocytic Leukemia (CLL). Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Predictors of Health-Related Quality of Life in Adults With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Overview
The study aims to improve our understanding of how quality of life, fatigue, and symptoms change over 2 years when participants are treated for chronic lymphocytic leukemia or small lymphocytic lymphoma. We will compare two types of treatment to help future patients with chronic lymphocytic leukemia or small lymphocytic lymphoma know what to anticipate.
Interventions
- Drug Bruton's tyrosine kinase inhibitor
BTKi - Drug B-Cell Lymphoma 2 Protein Inhibitor
BCL2i
Primary outcome measures
- Health Related Quality of Life (HRQOL) [Time frame: Up to 2 years]
- HRQOL predictors [Time frame: Up to 2 years]
- Interactions with treatment [Time frame: Up to 2 years]
Eligibility criteria
Inclusion criteria
- All patients with pathology-confirmed diagnoses of CLL who are within seven days of starting treatment with a BTKi +/- an anti-CD 20 monoclonal antibody or BCL2i with Obinutuzumab treatment will be included.
- Subjects must be able to read and speak English or Spanish at the 8th grade level.
Exclusion criteria
- Patients with dementia, traumatic brain injury, or individuals with central nervous system involvement of their leukemia will be excluded from study participation.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
United States · 1 center
- Moffitt Cancer Center — Tampa
Identifiers
NCT: NCT07030400 · MCC-23558